A randomized controlled trial comparing the efficacy and safety of oral tofacitinib versus methotrexate in moderate to severe alopecia areata

My research hypothesis is that methotrexate is non-inferior to tofacitinib in treating moderate to severe alopecia areata. In our research, we evaluated the SALT score, Scalp hair assessment PRO score at every month, and DLQI, and PHQ scores at baseline, at 6 months and 9 months of study period. we also evaluated side effects of both drugs at each visit.